Carlos Henrique Del Carlo: HFpEF Reimagined as an Adipose Tissue Driven Disease
Carlos Henrique Del Carlo, Collaborating Professor at University of São Paulo Medical School, shared a post on LinkedIn:
”HFpEF: Does it start in the Heart — or in the Adipose Tissue?
The traditional heart failure model focuses predominantly on the myocardium. However, the ‘Adipokine Hypothesis,’ recently proposed by Milton Packer (JACC 2025), suggests a radical paradigm shift: HFpEF may actually be the cardiac manifestation of systemic visceral adipose tissue dysfunction.
In this framework, adipose tissue is not merely an energy reservoir; it is an active endocrine organ that dictates cardiovascular biology.
The Proposed Pathophysiological Cascade:
- Visceral Adiposity: Expansion and dysfunctional transformation of adipose tissue (adipopathy).
- Adipokine Imbalance: A decline in cardioprotective molecules (Domain I) and a surge in pro-inflammatory and anti-natriuretic signals (Domain III).
- Systemic Inflammation: Microvascular oxidative stress and reduced nitric oxide bioavailability.
- Sodium Retention: Plasma volume expansion mediated by adipose biology, occurring even before overt cardiac failure.
- Myocardial Fibrosis: The heart as the “end-organ” target of a systemic insult that began in the periphery.
Why does this change our practice?
It explains why the most impactful therapies today – such as SGLT2 inhibitors and GLP-1 receptor agonists – are so effective: they target the metabolic and inflammatory substrate, not just cardiac mechanics.
When treating HFpEF, we are no longer just managing congestion; we are attempting to modulate the biological drivers of the disease.
Question for debate: Do you believe that, in the future, HFpEF management will be guided primarily by the biology of inflammation and adipose tissue, rather than just hemodynamics?
Reference: Packer M. The Adipokine Hypothesis of Heart Failure With a Preserved Ejection Fraction. J Am Coll Cardiol. 2025;86(16):1 801-1815.
Check the infographic below (produced with NotebooLM) for a visual summary of the adipokine hypothesis of HFpEF.”
Marwan Refaat Tenured Professor of Medicine, Biochemistry and Molecular Genetics at the American University of Beirut, shared this post on Linkedin, adding:
”Cardiovascular-kidney-metabolic (CKM) syndrome HFpEF Metabolic-Obese phenotype Visceral adiposity Systemic inflammation Microvascular dysfunction.”
Stay updated with Hemostasis Today.
-
Oct 18, 2026, 02:43Priya Sriskandarajah: Diagnosis and Management of PV and JAK2-Unmutated Erythrocytosis
-
Oct 18, 2026, 02:41C. Michael Gibson: A Meta-Analysis of DOACs and DAPT After Left Atrial Appendage Closure
-
Oct 18, 2026, 02:27What Hematologists Should Remember About the Person Behind the Platelet Count – ASH
-
Oct 18, 2026, 01:44Marta Velia Antonini: How to Deliver CRRT during ECMO?
-
Oct 18, 2026, 01:19Aamir Saeed: Anticoagulation, Cirrhosis, and Other Risk Factors for Post-ERCP Bleeding
-
Oct 18, 2026, 00:33Elad Asher: Does Opening the Clot Change How a Patient Feels Three Months Later?
-
Oct 18, 2026, 00:22Richa Sharma: Evaluating Heterogeneity in Anticoagulation Treatment Effects in Cryptogenic Stroke
-
Oct 18, 2026, 00:07Irem Karaman Sebin: The Evidence Favoring Warfarin in High-Risk Antiphospholipid Syndrome
-
Oct 18, 2026, 00:07Emma Stevens: Lighting Up Buildings in Red and Blue for World Thrombosis Day